144 related articles for article (PubMed ID: 10623802)
1. Analysis of the requirements for the induction of CD4+ T cell alloantigen hyporesponsiveness by ex vivo anti-CD40 ligand antibody.
Taylor PA; Panoskaltsis-Mortari A; Noelle RJ; Blazar BR
J Immunol; 2000 Jan; 164(2):612-22. PubMed ID: 10623802
[TBL] [Abstract][Full Text] [Related]
2. CD4(+) T cells tolerized ex vivo to host alloantigen by anti-CD40 ligand (CD40L:CD154) antibody lose their graft-versus-host disease lethality capacity but retain nominal antigen responses.
Blazar BR; Taylor PA; Noelle RJ; Vallera DA
J Clin Invest; 1998 Aug; 102(3):473-82. PubMed ID: 9691083
[TBL] [Abstract][Full Text] [Related]
3. Blockade of CD40 ligand-CD40 interaction impairs CD4+ T cell-mediated alloreactivity by inhibiting mature donor T cell expansion and function after bone marrow transplantation.
Blazar BR; Taylor PA; Panoskaltsis-Mortari A; Buhlman J; Xu J; Flavell RA; Korngold R; Noelle R; Vallera DA
J Immunol; 1997 Jan; 158(1):29-39. PubMed ID: 8977172
[TBL] [Abstract][Full Text] [Related]
4. Blockade of the CD40-CD40 ligand pathway potentiates the capacity of donor-derived dendritic cell progenitors to induce long-term cardiac allograft survival.
Lu L; Li W; Fu F; Chambers FG; Qian S; Fung JJ; Thomson AW
Transplantation; 1997 Dec; 64(12):1808-15. PubMed ID: 9422424
[TBL] [Abstract][Full Text] [Related]
5. CD40-CD40 ligand-independent activation of CD8+ T cells can trigger allograft rejection.
Jones ND; Van Maurik A; Hara M; Spriewald BM; Witzke O; Morris PJ; Wood KJ
J Immunol; 2000 Jul; 165(2):1111-8. PubMed ID: 10878390
[TBL] [Abstract][Full Text] [Related]
6. Blockade of CD86 and CD40 induces alloantigen-specific immunoregulatory T cells that remain anergic even after reversal of hyporesponsiveness.
Koenen HJ; Joosten I
Blood; 2000 May; 95(10):3153-61. PubMed ID: 10807782
[TBL] [Abstract][Full Text] [Related]
7. Blocking CD40 - CD154 and CD80/CD86 - CD28 interactions during primary allogeneic stimulation results in T cell anergy and high IL-10 production.
Van Gool SW; Vermeiren J; Rafiq K; Lorr K; de Boer M; Ceuppens JL
Eur J Immunol; 1999 Aug; 29(8):2367-75. PubMed ID: 10458748
[TBL] [Abstract][Full Text] [Related]
8. Sustained expression of CD154 (CD40L) and proinflammatory cytokine production by alloantigen-stimulated umbilical cord blood T cells.
Matthews NC; Wadhwa M; Bird C; Borras FE; Navarrete CV
J Immunol; 2000 Jun; 164(12):6206-12. PubMed ID: 10843672
[TBL] [Abstract][Full Text] [Related]
9. The role of the CD40 pathway in alloantigen-induced hyporesponsiveness in vivo.
Niimi M; Pearson TC; Larsen CP; Alexander DZ; Hollenbaugh D; Aruffo A; Linsley PS; Thomas E; Campbell K; Fanslow WC; Geha RS; Morris PJ; Wood KJ
J Immunol; 1998 Nov; 161(10):5331-7. PubMed ID: 9820506
[TBL] [Abstract][Full Text] [Related]
10. Induction of CD4+ T cell alloantigen-specific hyporesponsiveness by IL-10 and TGF-beta.
Zeller JC; Panoskaltsis-Mortari A; Murphy WJ; Ruscetti FW; Narula S; Roncarolo MG; Blazar BR
J Immunol; 1999 Oct; 163(7):3684-91. PubMed ID: 10490963
[TBL] [Abstract][Full Text] [Related]
11. CD40-CD40 ligand interactions are critical in T-B cooperation but not for other anti-viral CD4+ T cell functions.
Oxenius A; Campbell KA; Maliszewski CR; Kishimoto T; Kikutani H; Hengartner H; Zinkernagel RM; Bachmann MF
J Exp Med; 1996 May; 183(5):2209-18. PubMed ID: 8642330
[TBL] [Abstract][Full Text] [Related]
12. Differential effect of CTLA4Ig on murine graft-versus-host disease (GVHD) development: CTLA4Ig prevents both acute and chronic GVHD development but reverses only chronic GVHD.
Via CS; Rus V; Nguyen P; Linsley P; Gause WC
J Immunol; 1996 Nov; 157(9):4258-67. PubMed ID: 8892665
[TBL] [Abstract][Full Text] [Related]
13. Blockade of CD28-B7, but not CD40-CD154, prevents costimulation of allogeneic porcine and xenogeneic human anti-porcine T cell responses.
Lee RS; Yamada K; Womer KL; Pillsbury EP; Allison KS; Marolewski AE; Geng D; Thall AD; Arn JS; Sachs DH; Sayegh MH; Madsen JC
J Immunol; 2000 Mar; 164(6):3434-44. PubMed ID: 10706740
[TBL] [Abstract][Full Text] [Related]
14. CTLA4 signals are required to optimally induce allograft tolerance with combined donor-specific transfusion and anti-CD154 monoclonal antibody treatment.
Zheng XX; Markees TG; Hancock WW; Li Y; Greiner DL; Li XC; Mordes JP; Sayegh MH; Rossini AA; Strom TB
J Immunol; 1999 Apr; 162(8):4983-90. PubMed ID: 10202046
[TBL] [Abstract][Full Text] [Related]
15. Mucosally induced systemic T cell unresponsiveness to ovalbumin requires CD40 ligand-CD40 interactions.
Kweon MN; Fujihashi K; Wakatsuki Y; Koga T; Yamamoto M; McGhee JR; Kiyono H
J Immunol; 1999 Feb; 162(4):1904-9. PubMed ID: 9973457
[TBL] [Abstract][Full Text] [Related]
16. Colitis induced by enteric bacterial antigen-specific CD4+ T cells requires CD40-CD40 ligand interactions for a sustained increase in mucosal IL-12.
Cong Y; Weaver CT; Lazenby A; Elson CO
J Immunol; 2000 Aug; 165(4):2173-82. PubMed ID: 10925304
[TBL] [Abstract][Full Text] [Related]
17. CD40 ligand blockade induces CD4+ T cell tolerance and linked suppression.
Honey K; Cobbold SP; Waldmann H
J Immunol; 1999 Nov; 163(9):4805-10. PubMed ID: 10528180
[TBL] [Abstract][Full Text] [Related]
18. Regulation of cytoplasmic, surface and soluble forms of CD40 ligand in mouse B cells.
Wykes M; Poudrier J; Lindstedt R; Gray D
Eur J Immunol; 1998 Feb; 28(2):548-59. PubMed ID: 9521065
[TBL] [Abstract][Full Text] [Related]
19. Induction of alloantigen-specific tolerance by B cells from CD40-deficient mice.
Holländer GA; Castigli E; Kulbacki R; Su M; Burakoff SJ; Gutierrez-Ramos JC; Geha RS
Proc Natl Acad Sci U S A; 1996 May; 93(10):4994-8. PubMed ID: 8643517
[TBL] [Abstract][Full Text] [Related]
20. Induction of alloantigen-specific T cell tolerance through the treatment of human T lymphocytes with wortmannin.
Taub DD; Murphy WJ; Asai O; Fenton RG; Peltz G; Key ML; Turcovski-Corrales S; Longo DL
J Immunol; 1997 Mar; 158(6):2745-55. PubMed ID: 9058809
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
